RESEARCH ARTICLE

Recovery of physical function in lung transplant recipients with sarcopenia

Etsuhiro Nikkuni1†, Takashi Hirama2,3*, Kazuki Hayasaka2, Sakiko Kumata2, Shinichi Kotan2, Yui Watanabe2, Hisashi Oishi2, Hiromichi Niikawa2, Masahiro Kohzuki4 and Yoshinori Okada2,3

Abstract

Background: Lung transplant (LTX) can provide a survival benefit and improve physical function for selected patients with advanced pulmonary disease. Sarcopenia is a systemic muscle-failure that can be found in a variety of life stages and disabilities. In this study, we follow the evolution of each variable defined in sarcopenia and the outcomes in LTX recipients with post-transplant sarcopenia.

Methods: Patients who underwent LTX at Tohoku University Hospital between 2013 and 2018 were consecutively included in the retrospective cohort study, with follow-up to 2019. Sarcopenia was defined by low muscle mass (the cross-sectional area (CSA) of erector spinae muscle (ESM) in thoracic CT with a threshold < 17.24 cm²/m²) and either low muscle strength (hand-grip with a threshold of < 26 kg in males and of < 18 kg in females) or physical performance (6-min walk distance with a threshold < 46.5% of predicted distance).

Results: Fifty-five recipients were included into the study, of whom 19 patients were defined as sarcopenic and 36 as non-sarcopenic. The muscle mass improved after transplant in both sarcopenic and non-sarcopenic individuals: the median ESM-CSA enlarged from 17.25 cm²/m² in 2 months post-LTX to 18.55 cm²/m² in 12 months (p < 0.001) and 17.63 cm²/m² in 36 months (p < 0.001) in non-sarcopenic individuals, while in sarcopenic patients it improved from 13.36 cm²/m² in 2 months to 16.31 cm²/m² in 12 months (p < 0.005) and 18.01 cm²/m² in 36 months (p < 0.001). The muscle mass in sarcopenia substantially recovered to close to non-sarcopenic conditions within 36-months (p < 0.001 in 2 months and p = 0.951 in 36 months). Accordingly, muscle strength and physical performance in both groups improved over time. No difference in survival was seen in both groups (Log-rank p = 0.096), and sarcopenia was not associated with an overall hazard of death (p = 0.147). There was no difference in the cumulative incidence of chronic lung allograft dysfunction between patients with or without sarcopenia (Log-rank p = 0.529).

Conclusions: Even patients with post-transplant sarcopenia have a chance to recover physical function to levels close to those without sarcopenia several years post LTX.

Keywords: Lung transplant, Sarcopenia, Erector spine muscle (ESM), Hand-grip, Six-min walk distance (6MWD), Muscle

*Correspondence: thirama@icloud.com
†Etsuhiro Nikkuni and Takashi Hirama contributed equally to this work
3 Division of Organ Transplantation, Tohoku University Hospital, Sendai, Miyagi, Japan
Full list of author information is available at the end of the article
quality with high accuracy is not well standardized [1]. Sarcopenia is a systemic muscle-failure and is, although previously considered to be primarily associated with age-associated muscle disease in older people, currently found in a variety of life stages [2] and disabilities [3–5]. As documented in guidelines [6–8], measurement of muscle quantity, muscle strength and physical performance is recommended for the diagnosis of sarcopenia.

Although LTX is becoming increasingly common, Japan has a unique profile owing to a severe donor-shortage with 0.99 donations per million [9]: a strict age limit has been set up for listing (younger than 55 years old for a double LTX and 60 for a single), the number of single LTX outnumbers that of the double, and the mean waiting time is over 900 days [10, 11]. Therefore, LTX recipients in Japan are relatively young but become physically weakened during long waiting periods. Given those facts, it is conceivable that many LTX recipients, although this has not been evaluated, became post-operatively sarcopenic due to the progression of pulmonary disease during the long waiting time and/or post-transplant complications.

A recent systematic review noted that few studies have examined the prevalence of sarcopenia in LTX using the consensus definition and indicated that additional studies to assess sarcopenia with standardization of measurement techniques and incorporation of clinical outcomes were needed [12]. Therefore, the threshold for each variable to define sarcopenia was setup, and the medical chart of LTX recipients were retrospectively reviewed. We aimed to see how each variable related to physical and functional ability changed with each passing year and herein report the outcomes in LTX recipients with post-transplant sarcopenia.

Methods
Study design and data collection
Patients who underwent LTX at Tohoku University Hospital (TUH) between January 2013 and December 2018 were consecutively included in the retrospective cohort study, with follow-up extending to December 2019. LTX recipients who were younger than 18 years old or died within a year after transplant were excluded from the study. Baseline data were collected at the time of transplantation, and follow-up data were gathered monthly until hospital discharge, as well as at month 6, and annually post-transplant. All methods were performed in accordance with the Declaration of Helsinki. In light of the retrospective design, the requirement of informed consent was waived and the study protocol was approved by the Ethics Committee Tohoku University Graduate School of Medicine (Institutional Review Board number 2020-1-388). We disclosed information on the implementation of the research and ensured the opportunity for research subjects to refuse participation by posting the information disclosure materials approved by the Ethics Committee on the website of the Graduate School of Medicine, Tohoku University.

Management of LTX and definition of variables
All recipients received the same immunosuppression protocol in our centre [16], 16, with basiliximab for induction. Immunosuppression was maintained using tacrolimus targeting C0 level of 10–14 ng/ml for the first 6 months, 9–13 ng/ml up to 12 months and 8–10 ng/ml thereafter, mycophenolate at 1500 mg ≥50 kg or 1000 mg for <50 kg as tolerated and prednisolone at 1.0 mg/kg for the first 4 days, tapering gradually to 5 mg. When the patients could not tolerate tacrolimus or mycophenolate, cyclosporine or azathioprine was the alternative, respectively. No recipients received rituximab or rabbit anti-thymocyte globulin in the study period. Duration of ventilation was defined as the first day of extubation from the invasive mechanical ventilation after the surgery. The requirement of continuous renal replacement therapy (CRRT) for post-operative acute kidney injury was previously documented [16]. The presence of primary graft dysfunction at 24, 48 and 72 h after the graft perfusion was evaluated based on ISHLT consensus [18]. Acute allograft rejection, considered when there was an acute drop in lung function without episodes of infection or mechanical complications including pleural effusion, airway stenosis or native lung hyperinflation, was treated with a bolus of methylprednisolone at 500 mg for 3 consecutive days, followed by tapering doses of prednisone back down to 5 mg. Chronic lung allograft dysfunction (CLAD) was defined by a substantial (≥20%) and persistent (≥3 months) decline in FEV1 from the baseline value beyond the first year post-transplant [19].

Definition of sarcopenia
Post-transplant sarcopenia was assessed at month 2 and 6, and annually after LTX. Sarcopenia was defined by low muscle mass and either low muscle strength or physical performance [6, 7] (Table 1). LTX recipients who did not fulfil the definition of sarcopenia were categorized as non-sarcopenia. The low muscle mass was characterized by the cross-sectional area (CSA) of erector spinae muscle (ESM) in thoracic CT with a threshold <17.24 cm²/m² based on the study from the Japanese population [13]. Images of ESM-CSA were acquired on Toshiba Aquilion ONE scanner at each clinical assessment, analyzed with WeVIEW Z-edition (Hitachi, Ltd, Tokyo, Japan) (Fig. 1). Briefly, the border of ESM-CSA was outlined, and the area (cm²) was then normalized to body surface area (BSA) [13]. Muscle strength was assessed using peak
hand-grip force on the dominant hand with a dynamometer (Takei Scientific Instruments Co., Ltd, Nigata, Japan), and the low muscle strength was determined by hand-grip with a threshold of < 26 kg in males and of < 18 kg in females [7]. The trend of hand-grip strength was followed with actual and %predicted values [14]. The low physical performance was determined by 6-min walk distance (6MWD) with a threshold < 46.5% of predicted distance [15].

**Table 1** The definition of sarcopenia in lung transplant recipients

| Variable          | Clinical practice                                                                 | Threshold                      |
|-------------------|-----------------------------------------------------------------------------------|--------------------------------|
| [1] Muscle mass   | The cross-sectional area of erector spinae muscle/body surface area                | < 17.24 cm²/m²                |
| [2] Muscle strength | Handgrip strength                                                                  | Men: < 26 kg, Women: < 18 kg  |
| [3] Physical performance | % predicted six-min walk distance                                                  | < 46.5%                       |

Sarcopenia was defined by [1] low muscle mass and either [2] low muscle strength or [3] physical performance.

Post-transplant rehabilitation

Physical rehabilitation was started within 24 h post-operatively, aiming early mobilization, secretion clearance, breathing exercises, building upper and lower extremity range of motion and posture improvement. After being discharged from intensive care unit (ICU), reassessing supplemental oxygen requirements, balancing activities and transferring from bed to chair were included in the early in-patient rehabilitation. Lower extremity strength and gait speed were daily assessed in the rehabilitation unit in the late in-patient rehabilitation in order for the recipients to be deemed safe and independent for discharge home. ESM-CSA through thoracic CT, hand-grip strength, 6MWD, lung function and body mass index (BMI) were assessed monthly until hospital discharge, as well as at month 6, and annually post-transplant. After the surgery, LTX recipients remained in the hospital until adequate physical recovery and post-transplant rehabilitation continued to be provided during the hospital stay.

**Data analysis**

The variables between sarcopenia and non-sarcopenia were shown in percentage or medians (interquartile range (IQR)) as appropriate, and the difference in baseline data were assessed with chi-square or Fisher's exact tests for categoric variables and Mann-Whitney U test for continuous variables. Changes in follow-up data with respect to the first fully clinical/physical assessment done in 2 months post-LTX were analyzed by Wilcoxon signed-rank test, and the differences across groups by Mann-Whitney U test. Risk factors associated with post-transplant sarcopenia were assessed using multivariable logistic regression models, and those for mortality were analyzed using a Cox proportional hazards model. The Kaplan-Meier method was used to model time-to-event outcomes, and differences across groups were calculated with the log-rank test. Unadjusted survival analyses were performed to avoid overfitting due to the small sample size.
size. P values of < 0.05 were considered statistically significant. Statistical analyses and graph generation were performed with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA), Jamovi (Version 0.9, retrieved from https://www.jamovi.org) and StatPlus:macLE (AnalystSoft; Walnut, California, US).

**Results**

**Characteristics of patients with sarcopenia versus non-sarcopenia**

Sixty-two patients underwent LTX at TUH between 2013 and 2018, from whom 4 died within a year after transplantation (one died due to invasive aspergillosis, another due to esophageal fistula and the others due to primary graft dysfunction) and 3 pediatric cases were excluded from the analysis. Other 55 LTX recipients were included in the study, of whom the status of whether they were sarcopenic or not was assessed at 2 months post-LTX. Of these, 19 patients were defined as sarcopenic and 36 as non-sarcopenic (Fig. 2, Table 2). Median age at the time of LTX was 44 (IQR 33–50) without difference between sarcopenic and non-sarcopenic individuals ($p = 0.878$). Females accounted for 52.7% (29/55) of all recipients, with female dominance in sarcopenia (63.2%, 12/19) relative to non-sarcopenia (47.2%, 17/36) albeit without significance ($p = 0.260$). Transplant procedures including 49.1% of single (27/55), 49.1% of double (27/55) and 1.8% of living-donor (1/55) were done almost equally in both groups ($p = 0.528$). Transplant procedures including 49.1% of single (27/55), 49.1% of double (27/55) and 1.8% of living-donor (1/55) were done almost equally in both groups ($p = 0.528$). There was no statistic difference in LTX between groups ($p = 0.550$), with pulmonary vascular disease at 18.2% (10/55), restrictive at 25.5% (14/55), obstructive at 36.4% (20/55), suppurative at 3.6% (2/55) and others at 5.4% (3/55). Despite sarcopenia defined by low muscle mass and physical function, pre-transplant body mass index and walk distance were not different at the time of listing ($p = 0.815$ and 0.524, respectively).

Median waiting time was similar with 26 months (IQR 16–68) in sarcopenia and 26 (IQR 17–35) in non-sarcopenia. No LTX recipients were bridged on extracorporeal membrane oxygenation (ECMO) or mechanical ventilation (MV). Moreover, no significant difference was found in donor age ($p = 0.411$) and ischemic time ($p = 0.502$) between both groups. Post-operative condition and complications were reviewed, showing that ICU stay was longer in sarcopenia (29 days (IQR 16–68)) than that of non-sarcopenia (15 days (IQR 7–31), $p = 0.024$). Length of MV and hospital stay was numerically longer in sarcopenia but not statistically ($p = 0.052$ and 0.060, respectively). It was notable that no risk factors associated with post-transplant sarcopenia at 2 months were identified among variables including age, gender, LTX procedure, ICU stay and the length of hospitalization (Table 3).

**A trend in ESM-CSA in patients after lung transplant**

The status of whether they were considered post-transplant sarcopenia or not was assessed in all recipients at month 2, and variables that can be associated with sarcopenia were compared at month 6 and annually after LTX. Muscle mass plays an important role in appraising sarcopenia and the trend in ESM-CSA through thoracic CT was shown in Fig. 3a, illustrating that ESM-CSA improved over time in non-sarcopenic recipients for up to 24 months after transplantation (e.g. median ESM-CSA of 17.78 cm²/m² in 6 months ($p < 0.005$), 18.55 cm²/m² in 12 months ($p < 0.001$) and 17.63 cm²/m² in 36 months ($p < 0.001$), compared to 17.25 cm²/m² in 2 months after LTX). Likewise, the area of thoracic muscle drastically enlarged after LTX in sarcopenic patients from median ESM-CSA of 13.36 cm²/m² in 2 months to 14.86 cm²/m² in 6 months ($p < 0.01$), 16.31 cm²/m² in 12 months ($p < 0.005$) and 18.01 cm²/m² in 36 months ($p < 0.001$). Although ESM-CSA in

---

**Fig. 2** Study flow

---

**Table 2**

| LTX recipients (n=55) |
|-----------------------|
| Died within 1 year after lung transplant (n=4) |
| Pediatric lung transplant (n=3) |

**Table 3**

| Sarcopenia at 2 months post transplant (n=19) |
| No sarcopenia at 2 months post transplant (n=36) |
non-sarcopenic conditions was significantly more massive than that of sarcopenic individuals at 2 months after transplantation (median of 17.25 cm²/m² in non-sarcopenia vs 13.36 cm²/m² in sarcopenia, \( p < 0.001 \)), the difference became less significant with each passing year and was almost negligible 36 months after LTX (median of 17.63 cm²/m² in non-sarcopenia vs 18.01 cm²/m² in sarcopenia, \( p = 0.951 \)). This indicated that even LTX recipients who were sarcopenic after the

| Patients' characteristics | Total (n=55) | Sarcopenia (n=19) | Non-sarcopenia (n=36) | \( P \)-value |
|---------------------------|-------------|------------------|----------------------|-------------|
| Age at LTX, median (IQR)  | 44 (33–50)  | 45 (34–50)       | 44 (33–50)           | 0.878       |
| Female, n (%)             | 29 (52.7%)  | 12 (63.2%)       | 17 (47.2%)           | 0.260       |
| LTX procedure, n (%)      |             |                  |                      | 0.529       |
| Single                    | 27 (49.1%)  | 8 (42.1%)        | 19 (52.8%)           |            |
| Double                    | 27 (49.1%)  | 11 (57.9%)       | 17 (47.2%)           |            |
| Living-donor              | 1 (1.8%)    | 1 (5.3%)         | 0 (0.0%)             |            |
| LTX indication, n (%)     |             |                  |                      | 0.550       |
| Pulmonary Vascular Disease| 10 (18.2%)  | 5 (26.3%)        | 5 (13.9%)            |            |
| Restrictive Lung Disease | 14 (25.5%)  | 4 (21.1%)        | 10 (27.8%)           |            |
| Obstructive Lung Disease  | 20 (36.4%)  | 8 (42.1%)        | 12 (33.3%)           |            |
| Suppurative Lung Disease  | 8 (14.5%)   | 1 (5.3%)         | 7 (19.4%)            |            |
| Others                    | 3 (5.4%)    | 1 (5.3%)         | 2 (5.6%)             |            |
| Pre- and intra-operative condition | | | | |
| 6MWD (m), median (IQR)    | 318 (216–373)| 316 (221–387)    | 318 (204–369)       | 0.524       |
| Body-mass index (kg/m²), median (IQR) | 18.0 (17.0–22.0)| 18.0 (17.0–24.0)| 18.5 (16.3–21.0) | 0.815 |
| On supplemental oxygen, n (%) | 49 (89.1%) | 17 (89.5%) | 32 (88.9%) | 0.999 |
| Diabetes, n (%)           | 4 (7.3%)    | 3 (15.8%)        | 1 (2.8%)             | 0.077       |
| Connective tissue disease, n (%) | 9 (16.4%) | 3 (15.8%) | 6 (16.7%) | 0.933 |
| Chronic kidney disease, n (%) | 2 (3.6%) | 2 (10.5%) | 0 (0.0%) | 0.047 |
| Waiting time (month), median (IQR) | 26 (18–36) | 26 (19–37) | 26 (17–35) | 0.559 |
| Donor age, median (IQR)   | 43 (31–47)  | 43 (26–49)       | 42.5 (31.5–51)      | 0.411       |
| Ischemic time (min)       | 535 (452–697)| 483 (403–717)    | 555 (456–694)       | 0.323       |
| CMV mismatch (D+/R-), n (%) | 10 (18.2%) | 5 (26.3%) | 5 (13.9%) | 0.288 |
| Post-operative condition and complications | | | | |
| Primary graft dysfunction, n (%) | 45 (81.8%) | 17 (89.5%) | 28 (77.8%) | 0.465 |
| Requirement of tracheostomy, n (%) | 28 (50.9%) | 13 (68.4%) | 15 (42.7%) | 0.089 |
| Continuous renal replacement therapy, n (%) | 9 (16.4%) | 5 (26.3%) | 4 (11.1%) | 0.249 |
| Invasive mechanical ventilation (day), median (IQR) | 12 (4–29) | 18 (5–60) | 7 (4–21) | 0.052 |
| ICU stay (day), median (IQR) | 19 (9–39) | 29 (16–68) | 15 (7–31) | 0.024 |
| Hospital stay (day), median (IQR) | 85 (64–114) | 98 (64–170) | 81 (62–95) | 0.060 |
| Acute allograft rejection, n (%) | 9 (16.4%) | 3 (15.8%) | 6 (16.7%) | 0.999 |
| ESM-CSA (cm²/m²), median (IQR) | 15.7 (14.0–17.9) | 13.6 (12.6–14.9) | 17.3 (14.8–18.8) | <.0001 |
| %predicted hand-grip strength, median (IQR) | 54.0 (43.5–62.0) | 39.0 (28.0–49.0) | 58.0 (52.0–67.0) | <.0001 |
| Hand-grip strength (kg), median (IQR) | 20.0 (15.0–28.0) | 14.0 (11.8–17.3) | 24.0 (20.0–29.0) | <.0001 |
| %predicted 6MWD, median (IQR) | 65.0 (48.0–79.0) | 39.0 (31.0–64.0) | 74.5 (62.0–81.8) | <.0001 |
| 6MWD (m), median (IQR) | 447 (309–483) | 309 (195–399) | 476 (426–519) | <.0001 |
| Body-mass index (kg/m²), median (IQR) | 17.0 (15.0–21.0) | 17.0 (15.0–22.0) | 17.0 (16.0–20.0) | 0.989 |
| FEV1 (L), median (IQR) | 1.56 (1.30–1.95) | 1.36 (1.13–1.56) | 1.78 (1.37–2.02) | 0.013 |
| Follow-up duration in months, median (IQR) | 48 (26–70) | 43 (22–76) | 49 (27–67) | 0.571 |

*Bold values of \( p < 0.05 \) were considered statistically significant*
transplant procedure would be capable of rebuilding muscle volume years after transplantation.

**Table 3** Risk factors associated with post-transplant sarcopenia

| OR       | 95% CI          | p value |
|----------|----------------|---------|
| Age at LTX | 1.00 | 0.94–1.06 | 0.996 |
| Gender, female | 2.12 | 0.58–7.60 | 0.251 |
| LTX procedure, double | 0.79 | 0.17–3.65 | 0.765 |
| ICU stay | 1.02 | 0.98–1.06 | 0.398 |
| Hospital stay | 1.01 | 0.99–1.02 | 0.235 |

LTX, lung transplant; ICU, intensive care unit; OR, odds ratio and CI, confidence interval. Living-donor LTX (n = 1) was included double LTX.

On the other hand, 35 non-sarcopenic patients (97.2%) have remained in a status of non-sarcopenia and 1 recipient (2.8%) became sarcopenic. In a survival analysis with follow-up until December 2019, the sarcopenic status after LTX was not associated with higher mortality rates than non-sarcopenia (Log-rank $p=0.096$) (Fig. 4a). Risk factors for mortality after LTX were analyzed in a Cox model (Table 5), demonstrating that age was associated with mortality in both univariate (hazard ratio (HR) 1.12, 95% CI 1.02–1.24, $p=0.020$) and multivariate analysis (HR 1.19, 95% CI 1.03–1.38, $p=0.021$). Meanwhile, post-transplant sarcopenia, gender, transplant type and the length of ICU stay were not related to mortality. There was no difference in the cumulative incidence of CLAD between patients with or without sarcopenia (Log-rank $p=0.529$) (Fig. 4b).

**Discussion**

The muscle mass and strength related to sarcopenia were reviewed in LTX recipients and followed to see outcomes in a transplant centre in Japan. The ESM-CSA represents the muscle content in the thorax and is a vital factor to assess functional strength from the standpoint of sarcopenia. Several variables were used to define sarcopenia in LTX recipients [12]. Although the muscle amount based on the CSA of target muscles through thoracic CT was reported to be associated with the hospital stay or survival after LTX [3, 20–22], these studies examined sarcopenia only by the target muscles mass, not including muscle strength and physical performance. We herein demonstrated that the ESM-CSA steadily improved after transplant in both sarcopenic and non-sarcopenic, and the muscle size in sarcopenia substantially recovered close to that in non-sarcopenic individuals by 36-months. Accordingly, muscle strength and physical performance in both groups improved over time. Importantly, half of the patients with sarcopenia could deviate from such fragile status and be re-defined as non-sarcopenic in 12-months. Furthermore, no difference in survival and the cumulative incidence of CLAD was seen in sarcopenic vs non-sarcopenic patients. With those features in mind, post-transplant sarcopenia did not affect survival and graft failure and, more importantly, even physically and functionally frail patients have a chance to recover their condition close up to those in the non-sarcopenic years after LTX.

Six-minute walking test is a favorable scheme to measure physical functionality for patients with pulmonary disorder and oxygen requirement on exertion [23]. Despite its common use in clinical practice and the fact that pre-transplant long-walk distance was associated with post-transplant survival advantage [24], there are not many studies that evaluate sarcopenia using 6MWD.

**The transition of sarcopenic status in lung transplant recipients**

The sarcopenic status was re-evaluated in 12-month after LTX (Table 4). Nine (47.4%) out of 19 patients with sarcopenia were re-defined as sarcopenic, whereas 10 recipients (52.6%) were categorized as non-sarcopenic.
Therefore, the appropriate threshold of % predicted distance is not clearly studied among lung transplant recipients. With our data, LTX recipients were further categorized as infirmness (n = 18), defined with low muscle mass (ESM-CSA/BSA < 17.24 cm²/m²) and low muscle strength (Hand-Grip < 26 kg in male and < 18 kg in...
female) and robustness (n = 9), defined with ESM-CSA/BSA ≥ 17.24 cm²/m² and Hand-Grip ≥ 26 kg in male and ≥ 18 kg in female (Additional file 2: Figure 2). Based on that, the threshold at 72% predicted distance was tentatively setup with the upper margin of the cluster of infirmness group that contained the majority of the cases. Using the threshold, 33% (3/9) of the recipients classified as robustness could have poor physical performance, with which we should conduct a prospective study if such threshold would be appropriate to see the physical performance in LTX recipients. On the other hand, 6MWD in both sarcopenic and non-sarcopenic individuals could not reach 100% predicted distance, even several years after LTX. The task of how best to provide the appropriate physiotherapy in the late phase post-transplant should be addressed in the next study.

The study outcomes reminded us of conducting an additional analysis comparing post-transplant sarcopenia with pre-transplant condition. It is, however, not feasible to assess pre-transplant sarcopenia with the participants in the current study due to the transplant allocation system in Japan. As documented above, the mean waiting time is currently over 900 days in the country [11]. Meanwhile, Japan Organ Transplant Network (JOTN) allows LTX candidates to change the waiting status from active to inactive, according to the candidates’ requests. Under the system, some of the participants have been inactive for a while after listing, and the median waiting time is further prolonged. The median waiting time among the participants in the study (n = 55) was 26 months (IQR 19–34). Thus, pre-transplant data available shown in Table 2 were not sufficient and obtaining some variables relating to

| Table 4 | Outcome of patients with sarcopenia one year after lung transplant |
|--------|------------------|
| 2 months after LTX | 12 months after LTX |
| Sarcopenia (n = 19) | 9 (47.4%) | 10 (52.6%) |
| Non-sarcopenia (n = 36) | 1 (2.8%) | 35 (97.2%) |

LTX, lung transplant

| Table 5 | Hazard ratio for mortality from univariate and multivariate Cox model |
|---------|---------------------------------|
|          | HR | 95% CI     | p value |
| Sarcopenia | 3.83 | 0.70–20.93 | 0.122 |
| Age at LTX | 1.12 | 1.02–1.24 | 0.020 |
| Gender, female | 0.47 | 0.09–2.55 | 0.380 |
| LTX procedure, double | 1.51 | 0.27–8.26 | 0.638 |
| ICU stay | 1.02 | 0.99–1.05 | 0.139 |

|          | HR | 95% CI     | p value |
|---------|----|------------|
| Sarcopenia | 5.36 | 0.55–51.93 | 0.147 |
| Age at LTX | 1.19 | 1.03–1.38 | 0.021 |
| Gender, female | 0.30 | 0.04–2.22 | 0.236 |
| LTX procedure, double | 3.08 | 0.23–41.9 | 0.398 |
| ICU stay | 1.01 | 0.97–1.05 | 0.597 |

LTX, lung transplant; ICU, intensive care unit; HR, hazard ratio and CI confidence interval. Living-donor LTX (n = 1) was included double LTX
sarcopenia was not possible when the recipients were listed to JOTN (over 10 years ago in some recipients). We instead gathered information at 2 months after LTX when all recipients were fully assessed, which was compared with variables gathered at 6 months and annually thereafter. In light of the study design, the sarcopenic condition at 2 months may be influenced by not only advanced respiratory disease but also pre-transplant comorbidities, the transplant surgery, and/or post-transplant complications. In fact, ICU stay was significantly longer in the sarcopenic group \( (p=0.024) \), and a trend towards prolonged MV and hospitalization was also seen \( (p=0.052 \text{ and } 0.060, \text{ respectively}) \). Thus, it was uncertain whether pre-transplant condition, post-transplant complications or both led to post-transplant sarcopenia. To see possible associations of clinically important factors (age, gender and transplant type) and length of hospitalization and ICU stay with post-sarcopenia was retrospectively followed. All variables including the muscle mass, the muscle strength and the physical performance steadily improved over time after transplant. The muscle content of the thorax in sarcopenic patients substantially recovered to close to that of non-sarcopenic individuals within 36-months, and no difference in survival and the cumulative incidence of CLAD was seen between the groups. Although several limitations should be considered, our study suggests that even patients with sarcopenia have a chance to recover to physical and functional conditions close to those in non-sarcopenic individuals after LTX.

**Conclusions**

In summary, the threshold of the variables to define sarcopenia was setup and patients with post-transplant sarcopenia were retrospectively followed. All variables including the muscle mass, the muscle strength and the physical performance steadily improved over time after transplant. The muscle content of the thorax in sarcopenic patients substantially recovered to close to that of non-sarcopenic individuals within 36-months, and no difference in survival and the cumulative incidence of CLAD was seen between the groups. Although several limitations should be considered, our study suggests that even patients with sarcopenia have a chance to recover to physical and functional conditions close to those in non-sarcopenic individuals after LTX.

**Abbreviations**

BMI: Body mass index; BSA: Body surface area; CLAD: Chronic lung allograft dysfunction; CT: Computed tomography; ESM: Erector spine muscle; FEV1: Forced expiratory volume in the first second; JOTN: Japan organ transplant network; LTX: Lung transplant; 6MWD: Six-min walk distance.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01442-5.

**Additional file 1.** The trend in the hand-grip strength (kg) and 6-minute walk distance (m) shown by months after transplant.

**Additional file 2.** An attempt to setup the threshold of the physical performance based on %predicted 6-minute walk test.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

EN and TH are the guarantors of this manuscript. TH has full access to all of the data in the study and gathered information from the database. KH, ShKo, ShKo, YW, HO, HN and MK contributed substantially to the study design, the data analysis and interpretation, and wrote the manuscript. TH is responsible for the integrity of the data and the accuracy of the data analysis. All authors have read and approved the manuscript.

**Funding**

The collection, analysis, and interpretation of data were supported in a part by Tokyo-Hokenkai Byotai-Seiri Laboratory, Takeda Science Foundation, Grant-in-Aid for Scientific Research C (20K08509) and Grant-in-Aid for Young Scientists (20K17736). No additional external funding was received for this study.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

All methods were performed in accordance with the Declaration of Helsinki. In light of the retrospective design, the requirement of informed consent was waived and the study protocol was approved by the Ethics Committee Tohoku University Graduate School of Medicine (Institutional Review Board number 2020-1-388). We disclosed information on the implementation of the research and ensured the opportunity for research subjects to refuse participation by posting the information disclosure materials approved by the
Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Rehabilitation, Tohoku University Hospital, Sendai, Miyagi, Japan. 2 Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan. 3 Division of Organ Transplantation, Tohoku University Hospital, Sendai, Miyagi, Japan. 4 Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Received: 1 November 2020 Accepted: 18 February 2021

Published online: 16 April 2021

References
1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. https://doi.org/10.1093/ageing/afy169.
2. Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of sarcopenia. J Nutr Health Aging. 2008;12:427–32. https://doi.org/10.1007/BF02982703.
3. Hsu J, Krishnan A, Lin CT, Shah PD, Broderick SR, Higgins RSD, et al. Sarcopenia of the Psoas Muscles Is Associated With Poor Outcomes Following Lung Transplantation. Ann Thorac Surg. 2019;107:1082–8. https://doi.org/10.1016/j.jathcas.2018.10.006.
4. Benz E, Trajanonska K, Lahousse L, Schoufour JD, Terzikhan N, De Roos E, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2019;28:190049. https://doi.org/10.1183/16000617.0049-2019.
5. Moon SW, Choi JS, Lee SH, Jung KS, Jung JY, Kang YA, et al. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res. 2019;20:35. https://doi.org/10.1186/s12931-019-1001-6.
6. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People: Age Ageing. 2010;39:412–23. https://doi.org/10.1093/ageing/afq034.
7. Chen L-K, Liu L-K, Wuo J, Assantachai P, Auyeung T-W, Bahyah KS, et al. Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15:95–101. https://doi.org/10.1016/j.jamda.2013.11.025.
8. McLean RR, Sharidell MD, Alley AL, Cawthon PM, Fraga LA, Harris TB, et al. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. J Gerontol Ser A. 2014;69:S76–83. https://doi.org/10.1093/gerona/glu012.
9. International Registry In Organ Donation And Transplantation. Newsletter June 2020. Barcelona. 2020. https://www.irodat.org/.
10. Date H. Current status and problems of lung transplantation in Japan. J Thorac Dis. 2016;8:5631–6. https://doi.org/10.21037/jtd.2016.06.38.
11. Japan Organ Transplantation Network. Organ donation & transplantation data book 2017. Tokyo, 2017. https://www.jotnw.or.jp/datas/databook/.
12. Rozenberg D, Wickerson L, Singer LG, Mathur S. Sarcopenia in lung transplantation: a systematic review. J Hear Lung Transplant. 2014;33:1203–12. https://doi.org/10.1016/j.healun.2014.06.003.
13. Minegishi Y, Inoue S, Sato K, Abe K, Murano H, Furuyama K, et al. Smaller erector spinae muscle size is associated with inability to recover activities of daily living after pneumonia treatment. Respir Investig. 2019;57:191–7. https://doi.org/10.1016/j.resinv.2018.11.002.
14. Mathiowitz V, Kashman N, Volland G, Weber K, Dowle M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985;66:69–74.
15. Rozenberg D, Mathur S, Wickerson L, Chowdhury NA, Singer LG. frailty and clinical benefits with lung transplantation. J Hear Lung Transplant. 2018;37:1245–53. https://doi.org/10.1016/j.healun.2018.06.005.
16. Katahira M, Hiraama T, Eba S, Suzuki T, Notsuda H, Oishi H, et al. Impact of postoperative continuous renal replacement therapy in lung transplant recipients. Transplant Direct. 2020;6:e652. https://doi.org/10.1097/TXD.0000000000001013.
17. Kunita S, Hiraama T, Watanabe Y, Oishi H, Nikiwata H, Akiba M, et al. The fraction of sensitization among lung transplant recipients in a transplant center in Japan. BMC Pulm Med. 2020;20:256. https://doi.org/10.1186/s12890-020-01299-0.
18. Snell GL, Yuen RD, Weill D, Struebeier M, Garrity E, Reed A, et al. Report of the ISHLT Working Group on primary lung graft dysfunction, part I: definition and grading—a 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Hear Lung Transplant. 2017;36:1097–103. https://doi.org/10.1016/j.healun.2017.07.021.
19. Glanville AN, Verleden GM, Todd JL, Benden C, Calabrese P, Gottlieb J, et al. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome—a consensus report from the Pulmonary Council of the ISHLT. J Hear Lung Transplant. 2019;38:483–92. https://doi.org/10.1016/j.healun.2019.03.008.
20. Hoang V, Li GW, Kao CC, Drnovagil G, Parulekar AD. Determinants of pre-transplantation pectoral muscles area (PMA) and post-transplantation change in PMA in lung transplant recipients. Clin Transplant. 2017;31:e12897. https://doi.org/10.1111/ctr.12897.
21. Rozenberg D, Mathur S, Herridge M, Goldstein R, Schmidt H, Chowdhury NA, et al. Thoracic muscle cross-sectional area is associated with hospital length of stay post lung transplantation: a retrospective cohort study. Transpl Int. 2017;30:713–24. https://doi.org/10.1111/tri.12961.
22. Lee S, Paik HC, Haam SJ, Lee CY, Nam KS, Jung HS, et al. Sarcopenia of thoracic muscle mass is not a risk factor for survival in lung transplant recipients. J Thorac Dis. 2016;8:2011–7. https://doi.org/10.21037/jtd.2016.07.06.
23. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158:1384–7. https://doi.org/10.1164/ajrccm.158.5.9710086.
24. Castleberry AW, Englum BR, Snyder LD, Worni M, Osho AA, Gulack BC, et al. The utility of preoperative six-minute-walk distance in lung transplantation. Am J Respir Crit Care Med. 2015;192:843–52. https://doi.org/10.1164/rcrm.201409-1698OC.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.